Bruker (BRKR) Peer Comparison

$59.25

$2.19 (3.84%)

As on 27-Aug-2026 16:18EDT

Market cap

$9,075 Mln

Revenue (TTM)

$3,500 Mln

P/E Ratio

P/B Ratio

3.8

Div. Yield

0.3 %

Edit

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	9,075	12,753	10,906	9,762	10,222
Revenue ($ Mln)	3,500	1,505	613	2,589	785
Net Profit ($ Mln)	-71.20	160.59	-188.05	222.40	41.54
Net Margin (%)	-2.03	10.67	-30.68	8.59	5.29
RoE (%)	-3.21	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	3.84	8.41	16.38	1.26	4.84

Income Statement ($ Mln)

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	3,499.60	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	1,865.70	483.98	127.96	1,245.50	384.30
Gross Profit	1,577.70	942.44	393.22	1,343.60	347.62
Operating Expenses	1,507.40	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	126.50	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-28.10	203.83	-192.83	350.40	52.15
Provision for Tax	40.40	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-71.20	160.59	-188.05	222.40	41.54
Minority Interest	-6.70	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	2,400.20	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	-6.70	0.00	0.00	0.00	0.00
Non-Current Liabilities	2,393.60	210.18	135.71	2,116.80	705.49
Current Liabilities	1,204.70	233.78	102.33	961.30	132.66
Total Liabilities	6,241.40	1,826.52	893.49	10,576.50	2,949.70

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	3,827.90	630.60	404.74	7,231.50	1,749.63
Current Assets	2,225.00	1,344.12	515.78	3,020.50	1,200.55
Total Assets	6,241.40	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	1,915.70	212.71	102.84	1,203.70	690.94
Net Current Assets	1,020.30	1,110.35	413.45	2,059.20	1,067.90

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	134.10	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-196.50	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	135.10	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-0.20	11.76	-22.53	8.98	1.79
ROE (%)	-3.21	10.86	-28.10	3.04	1.97
ROA (%)	-0.95	7.95	-18.00	2.02	1.36
EBIT Margin (%)	0.50	13.63	-30.58	-5.99	9.87
Net Margin (%)	-2.03	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	1.65	17.55	41.55	1.37	16.49
EBIT Growth (%)	-90.88	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-189.45	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-189.62	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	32.61	17.33	-12.65	2.19	2.16

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-835.38	68.93	-34.59	--	189.42
Price / Book Value	2.92	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	29.51	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.76	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.04	0.01	0.00	0.06	0.01
Current Ratio	1.85	5.75	5.04	3.14	9.05
Quick Ratio	0.92	3.86	4.46	2.33	7.64
Interest Coverage	0.54	157.91	-38.31	8.18	3.36

	Bruker (BRKR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	25.01	12.65	22.67	17.06	20.09
Asset Turnover	0.47	0.74	0.59	0.24	0.26
Receivable days	76.38	46.54	60.95	65.39	72.41
Inventory Days	212.45	331.92	193.84	221.09	146.53
Payable days	44.21	26.16	60.19	37.02	29.05
Cash Conversion Cycle	244.62	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.